Table 2.

Involvement of the alternative pathway in lysis of neuraminidase-treated carcinoma cells by complement

Cells	Treatment*	Serum†	Lysis (%)
T47D	Control	NHS	38·0 ± 1·4
	NA	NHS	71·0 ± 15·1
	Control	RB	18·3 ± 3·6
	NA	RB	20·3 ± 6·7
	Control	RB + fB	33·0 ± 3·4
	NA	RB + fB	65·5 ± 14·0
SKOV3	Control	NHS	41·8 ± 6·1
	NA	NHS	72·3 ± 8·2
	Control	RB	22·5 ± 3·0
	NA	RB	27·8 ± 1·0
	Control	RB + fB	44·3 ± 5·7
	NA	RB + fB	78·8 ± 5·1
PC-3	Control	NHS	36·8 ± 7·9
	NA	NHS	70·5 ± 11·1
	Control	RB	19·5 ± 2·4
	NA	RB	24·8 ± 3·3
	Control	RB + fB	31·5 ± 6·6
	NA	RB + fB	76·5 ± 10·0

^*Cells were treated first with neuraminidase (NA) or PBS (control) and then lysed by antibody and serum. Percentage lysis was determined by trypan blue inclusion.

^†NHS, normal human serum; RB, human serum depleted of factor B (fB); RB + fB, RB supplemented with purified fB.